Insulin glargine biosimilar (HEC Pharm)

甘精胰岛素生物类似药（东阳光）

Report date: 2026/05/06 20:02:28

Base Information

Drug NameInsulin glargine biosimilar (HEC Pharm)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2021/11/02
Country/TerritoryUnited StatesSouth AfricaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesYichang Hec Changjiang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLannett Co IncSunshine Lake Pharma Co LtdLannett Company Inc +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AE04
Related LinksN/A